Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation

Abstract Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic dis...

Full description

Bibliographic Details
Main Authors: Ricardo Roa-Chamorro, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Fernando Jaén-Águila, Pablo González-Bustos, Miguel Ángel Rodríguez-Gil, Juan Diego Mediavilla-García
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-39057-x

Internet

https://doi.org/10.1038/s41598-023-39057-x

Similar Items